An observational validation study of the impact of Frailty on posttreatment adverse events and poor prognosis in patients with a patient with urological diseases

An observational validation study of the impact of Frailty on posttreatment adverse events and poor prognosis in patients with a patient with urological diseases - An observational validation study of the impact of Frailty on posttreatment adverse events and poor prognosis in patients with a patient with urological diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028533

Enrollment

600

Registered

2017-08-06

Start date

2017-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with urological diseases who undergo frailty assessments. Urological diseases include both malignant and non-malignant diseases.

Exclusion criteria

Exclusion criteria: Patients with urological diseases who could not undergo frailty assessments.

Design outcomes

Primary

Measure	Time frame
Primary outcomes: Predicting frailty related post-treatment adverse events using Frailty Discriminant score Secondary outcomes: Comparison of previously reported frailty assessment tools for diagnostic accuracy for frailty, Overall survival, Cancer-specific survival, Postoperative complication, Chemotherapy related to severe adverse events, Clinical indication for definitive therapies (surgery, chemotherapy and/or radiotherapy), Relationship between frailty and quality of life	—

Measure

Time frame

Primary outcomes: Predicting frailty related post-treatment adverse events using Frailty Discriminant score Secondary outcomes: Comparison of previously reported frailty assessment tools for diagnostic accuracy for frailty, Overall survival, Cancer-specific survival, Postoperative complication, Chemotherapy related to severe adverse events, Clinical indication for definitive therapies (surgery, chemotherapy and/or radiotherapy), Relationship between frailty and quality of life

—

Secondary

Measure	Time frame
This study is a part of our prospective observational study (UMIN000025057). We planned the inter-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) when we successfully developed our CGA tool.	—

Countries

Japan

Contacts

Public ContactSHINGO Hatakeyama

Hirosaki University Graduate School of Medicine Urology

shingorilla2@gmail.com0172395091

Outcome results